ArticleQuantitative imaging in medicine and surgery2026
Clinical prognostic value of imaging and immuno-hormonal markers in uterine leiomyoma.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine leiomyoma is a prevalent benign tumor arising from the smooth muscle cells of the uterine wall, profoundly affecting women's reproductive health and overall quality of life. Despite extensive studies on hormonal and molecular genetic mechanisms, its pathogenesis remains incompletely understood. Increasing evidence suggests that cytokines, growth factors, and immune-hormonal interactions may play a key role in tumor progression and recurrence. This study aimed to evaluate the prognostic significance of imaging, immunological, and hormonal markers in the assessment of antitumor immune response and clinical outcomes in women of reproductive age with uterine leiomyoma. Methods: A total of 61 women diagnosed with uterine leiomyoma were examined at the Gynecology Department of Bukhara Outpatient Polyclinic (OPC). Clinical, biochemical, hormonal, and immunological parameters were analyzed using standard laboratory assays and magnetic resonance imaging (MRI). Statistical analysis included comparative, correlational, and regression methods to identify prognostic indicators. Results: Hereditary predisposition, history of medical abortion, and excess body weight were identified as major risk factors. Elevated serum biomarker levels of vascular endothelial growth factor (VEGF) (>95.1 pg/mL), estradiol (>40.5 pg/mL), and fibroblast growth factor-1 (FGF-1) (>81.4 pg/mL) significantly increased the likelihood of leiomyoma development (P<0.05). Enhancing antiproliferative activity of transforming growth factor beta-2 (TGF-β2) and reducing progesterone synthesis reflected impaired growth-factor-mediated regulation and potential neoplastic transformation. Serum levels of cancer antigen 125 (CA-125) and cancer antigen 19-9 (CA-19-9) were significantly elevated in women with uterine leiomyoma compared with controls (P<0.0001). MRI findings demonstrated heterogeneous leiomyoma morphology with variable localization, vascularization, and nodular architecture. Macroscopic examination revealed well-circumscribed firm nodules with a characteristic whorled appearance. Histological analysis confirmed benign smooth muscle proliferation with interlacing fascicles, minimal atypia, connective tissue stroma, and variable fibrotic or vascular changes. Conclusions: Uterine leiomyoma is characterized by elevated tumor markers, hormonal dysregulation, inflammatory and angiogenic activation, and distinct radiological and morphological features. Integrated evaluation of biochemical, imaging, and histopathological parameters may improve diagnostic assessment, characterization of tumor heterogeneity, and individualized management strategies in women with uterine leiomyoma. Integration of imaging findings with immuno-hormonal biomarkers may improve early detection, risk stratification, and individualized management of uterine leiomyoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.